New Insights of Anti-cancer Immunity and Cancer Immune Evasion
A special issue of Immuno (ISSN 2673-5601). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 142
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer cells and malignant tumors operate a range of biochemical pathways which allow them to produce and activate proteins (known as immune checkpoints) and small molecular weight compounds capable of suppressing anti-cancer activities of immune cells. Recent evidence clearly demonstrated that immune evasion mechanisms operated by cancer cells include complex machinery. In order to successfully treat cancer employing patients’ immune system and helping it to deal with malignancies, a deep understanding of molecular basis of cancer immune evasion networks is required. The aim of this collection is to put together the manuscripts highlighting new discoveries and advances in anti-tumor immunity and cancer immune evasion machinery. We welcome submissions of research articles and short reports, clinical studies and clinical trials associated with cancer immune evasion machinery, anti-cancer immunity and immunotherapy of cancer. We also welcome expert reviews covering the aspects mentioned above.
Dr. Vadim Sumbayev
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Immuno is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anti-cancer immunity: molecular mechanisms
- cancer immune evasion machinery: molecular mechanisms
- immunotherapy of cancer
- immune checkpoint proteins and pathways
- small molecular weight compounds suppressing anti-cancer immunity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
